Abcam, ab251180, Anti-NAT2/AT-2 antibody [EPR15856] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal NAT2/AT-2 antibody. Carrier free. Suitable for ICC/IF, WB and reacts with Human, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR15856,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Rat, Human,
Applications:WB, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab251180 is the carrier-free version of
ab194114
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
NAT2 also known as N-acetyltransferase 2 or AT-2 is an important enzyme in drug metabolism. It catalyzes the acetylation process which plays a role in converting substances such as drugs and environmental chemicals into less active forms. This enzymatic activity requires co-factor acetyl-CoA. NAT2 has a molecular weight of about 33 kDa and is expressed mostly in liver and intestines. Its genetic polymorphisms influence enzyme activity leading to rapid or slow acetylator phenotypes among individuals.
Biological function summary
NAT2 participates in the metabolism of aromatic amines which includes the acetylation of drugs like isoniazid and sulfamethazine. NAT2 does not typically form complexes with other proteins but its activity affects the concentration of metabolites that can interact with other pathways or proteins. It regulates the bioavailability and potential toxicity of different chemical substances in the body by modifying their structure and reactivity impacting pharmacokinetics significantly.
Pathways
NAT2 is deeply involved in xenobiotic metabolism and Phase II drug metabolism pathways. It contributes directly to the N-acetylation pathway critical for the biotransformation of pharmaceuticals. NAT2 works in tandem with Cytochrome P450 enzymes which usually perform initial oxidative modifications on compounds destined for NAT2 acetylation. This interaction highlights NAT2's role in creating metabolic balance by processing potential toxins and facilitating their removal or detoxification from the body.
NAT2 polymorphisms play a critical role in susceptibility to certain conditions such as bladder cancer and drug-induced lupus erythematosus. Slow acetylator phenotypes are associated with higher risk of bladder cancer due to inefficient detoxification of carcinogens. Furthermore NAT2 interplays with proteins like N-acetyltransferase 1 (NAT1) influencing the biological responses and effectiveness of therapeutic strategies. Understanding the role of NAT2 in these disorders is essential for developing personalized medicine approaches to treatment.